Mirati Therapeutics shares are trading lower after the company announced the EMA's CHMP issued a negative opinion on the Conditional Marketing Authorization Application for KRAZATI for treatment of patients with KRASG12C -mutated advanced NSCLC.
Portfolio Pulse from Benzinga Newsdesk
Mirati Therapeutics shares are trading lower following the announcement that the EMA's CHMP issued a negative opinion on the Conditional Marketing Authorization Application for KRAZATI, a treatment for patients with KRASG12C -mutated advanced NSCLC.
July 21, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mirati Therapeutics' stock price is likely to be negatively impacted in the short term due to the negative opinion issued by EMA's CHMP on KRAZATI's marketing authorization application.
The negative opinion issued by EMA's CHMP on the marketing authorization application for KRAZATI, a product of Mirati Therapeutics, is a significant setback for the company. This could lead to a delay or even a denial in the approval of the drug, which would impact the company's revenues and hence, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100